[{"id":"037190b9-a29c-4950-8488-50ec828ead4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609592","created_at":"2021-02-11T16:55:29.685Z","updated_at":"2025-02-25T15:44:13.594Z","phase":"Phase 1","brief_title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","source_id_and_acronym":"NCT04609592","lead_sponsor":"Stanford University","biomarkers":" SSTR","pipe":" | ","alterations":" PGR expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-10-28"},{"id":"262cf44c-be15-41ea-888f-0c8ef3394bfa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04176848","created_at":"2021-01-18T20:22:17.239Z","updated_at":"2025-02-25T15:08:55.318Z","phase":"Phase 2","brief_title":"CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT04176848","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • ER • PGR • PLK4","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • ER • PGR • PLK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • ocifisertib (CFI-400945)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/10/2020","start_date":" 08/10/2020","primary_txt":" Primary completion: 09/15/2022","primary_completion_date":" 09/15/2022","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-08-09"},{"id":"d47949b4-79db-40bb-b143-95bc65160a6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02530489","created_at":"2021-01-18T12:14:13.966Z","updated_at":"2024-07-02T16:34:37.369Z","phase":"Phase 2","brief_title":"Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT02530489","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 amplification • HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification • HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • albumin-bound paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/04/2016","start_date":" 02/04/2016","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-07"},{"id":"b5216033-99a5-4f51-828d-87fa62fb0d17","acronym":"CAPItello-292","url":"https://clinicaltrials.gov/study/NCT04862663","created_at":"2021-04-28T13:53:54.000Z","updated_at":"2024-07-02T16:34:37.553Z","phase":"Phase 3","brief_title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","source_id_and_acronym":"NCT04862663 - CAPItello-292","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib)"],"overall_status":"Recruiting","enrollment":" Enrollment 895","initiation":"Initiation: 05/10/2021","start_date":" 05/10/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 08/14/2029","study_completion_date":" 08/14/2029","last_update_posted":"2024-06-06"},{"id":"e2962ecf-0b50-49e6-96a6-e28d8eca2ad1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05877859","created_at":"2023-05-26T15:07:09.164Z","updated_at":"2024-07-02T16:34:59.728Z","phase":"","brief_title":"Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab","source_id_and_acronym":"NCT05877859","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 04/10/2025","primary_completion_date":" 04/10/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-05-31"},{"id":"ffbe1180-1344-4782-86e6-9a29a87d3dae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03911453","created_at":"2021-01-18T19:15:05.344Z","updated_at":"2024-07-02T16:34:59.716Z","phase":"Phase 1","brief_title":"Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors","source_id_and_acronym":"NCT03911453","lead_sponsor":"University of Arizona","biomarkers":" HER-2 • PD-L1 • ER • PGR • PD-1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression • HRD • PGR expression","tags":["HER-2 • PD-L1 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression • HRD • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rubraca (rucaparib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/19/2019","start_date":" 04/19/2019","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 11/30/2024","study_completion_date":" 11/30/2024","last_update_posted":"2024-05-31"},{"id":"49b56574-d546-4ca7-a49a-b03317d41c4c","acronym":"ISIdE","url":"https://clinicaltrials.gov/study/NCT05552001","created_at":"2023-09-05T19:11:08.766Z","updated_at":"2024-07-02T16:35:00.022Z","phase":"Phase 3","brief_title":"Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer","source_id_and_acronym":"NCT05552001 - ISIdE","lead_sponsor":"UNICANCER","biomarkers":" HER-2 • ER • PGR • PD-1","pipe":" | ","alterations":" ER expression • PGR expression • ER amplification • PD-1 positive","tags":["HER-2 • ER • PGR • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER expression • PGR expression • ER amplification • PD-1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-05-30"},{"id":"ed815c0f-e035-457c-bdd2-620951dfd038","acronym":"","url":"https://clinicaltrials.gov/study/NCT06100874","created_at":"2023-10-25T19:14:19.283Z","updated_at":"2024-07-02T16:35:00.165Z","phase":"Phase 2","brief_title":"A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)","source_id_and_acronym":"NCT06100874","lead_sponsor":"Adrienne G. Waks","biomarkers":" HER-2","pipe":" | ","alterations":" PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/20/2023","start_date":" 11/20/2023","primary_txt":" Primary completion: 11/30/2026","primary_completion_date":" 11/30/2026","study_txt":" Completion: 11/30/2027","study_completion_date":" 11/30/2027","last_update_posted":"2024-05-30"},{"id":"ac428d9a-273b-4d56-88c0-0d08a880a183","acronym":"TUXEDO-3","url":"https://clinicaltrials.gov/study/NCT05865990","created_at":"2024-01-16T19:18:52.062Z","updated_at":"2024-07-02T16:35:03.380Z","phase":"Phase 2","brief_title":"HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease","source_id_and_acronym":"NCT05865990 - TUXEDO-3","lead_sponsor":"MedSIR","biomarkers":" HER-2 • ER • PGR • ERBB3 • TACSTD2","pipe":" | ","alterations":" HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression","tags":["HER-2 • ER • PGR • ERBB3 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e patritumab deruxtecan (U3-1402)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-16"},{"id":"8ba9e8f3-0202-4655-a1f4-6afdb8352cd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05455658","created_at":"2022-07-13T12:56:22.409Z","updated_at":"2024-07-02T16:35:05.151Z","phase":"Phase 2","brief_title":"STEMVAC in Patients With Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT05455658","lead_sponsor":"University of Washington","biomarkers":" HER-2 • ER • PGR • IFNG","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • ER • PGR • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-101 STEMVAC • Leukine (sargramostim)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-08"},{"id":"897909b1-c6e1-41f7-88be-83c1a5eb1e3b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02876107","created_at":"2021-01-18T14:07:14.833Z","updated_at":"2024-07-02T16:35:11.111Z","phase":"Phase 2","brief_title":"Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer","source_id_and_acronym":"NCT02876107","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • NODAL","pipe":" | ","alterations":" HER-2 negative • HER-2 expression • PGR expression","tags":["HER-2 • NODAL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Vectibix (panitumumab) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 10/06/2016","start_date":" 10/06/2016","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-04-05"},{"id":"89ab6e89-05c5-41d2-9c7b-7bfb72aee4a6","acronym":"NCI-2016-01913","url":"https://clinicaltrials.gov/study/NCT02996825","created_at":"2021-01-17T17:41:57.107Z","updated_at":"2024-07-02T16:35:12.045Z","phase":"Phase 1","brief_title":"Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer","source_id_and_acronym":"NCT02996825 - NCI-2016-01913","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • MUC16","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PGR • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Elahere (mirvetuximab soravtansine-gynx) • liposomal gemcitabine (FF-10832)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 02/09/2024","primary_completion_date":" 02/09/2024","study_txt":" Completion: 02/09/2024","study_completion_date":" 02/09/2024","last_update_posted":"2024-04-02"},{"id":"c78fd3b4-542c-4f48-8407-31637e45046d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04613674","created_at":"2021-01-19T20:33:05.685Z","updated_at":"2024-07-02T16:35:12.673Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT04613674","lead_sponsor":"Jiangsu HengRui Medicine Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab)"],"overall_status":"Completed","enrollment":" Enrollment 441","initiation":"Initiation: 12/09/2020","start_date":" 12/09/2020","primary_txt":" Primary completion: 09/14/2023","primary_completion_date":" 09/14/2023","study_txt":" Completion: 03/05/2024","study_completion_date":" 03/05/2024","last_update_posted":"2024-03-27"},{"id":"c85d0fbd-2933-415e-b05b-3c19d612d87f","acronym":"IMpassion131","url":"https://clinicaltrials.gov/study/NCT03125902","created_at":"2021-01-17T17:20:59.327Z","updated_at":"2024-07-02T16:35:12.920Z","phase":"Phase 3","brief_title":"A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT03125902 - IMpassion131","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • paclitaxel"],"overall_status":"Completed","enrollment":" Enrollment 653","initiation":"Initiation: 08/25/2017","start_date":" 08/25/2017","primary_txt":" Primary completion: 11/15/2019","primary_completion_date":" 11/15/2019","study_txt":" Completion: 01/17/2023","study_completion_date":" 01/17/2023","last_update_posted":"2024-03-26"},{"id":"9df7d698-3d6e-4fb5-9f2d-d1c17011273e","acronym":"IRIS","url":"https://clinicaltrials.gov/study/NCT04383275","created_at":"2021-01-18T21:09:55.347Z","updated_at":"2024-07-02T16:35:13.323Z","phase":"Phase 2","brief_title":"Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)","source_id_and_acronym":"NCT04383275 - IRIS","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • tamoxifen • capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 356","initiation":"Initiation: 08/23/2021","start_date":" 08/23/2021","primary_txt":" Primary completion: 05/15/2025","primary_completion_date":" 05/15/2025","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2024-03-22"},{"id":"a807a23b-d916-49a5-bf5d-9adada61ab5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05861271","created_at":"2023-05-16T17:06:46.295Z","updated_at":"2024-07-02T16:35:13.295Z","phase":"Phase 2","brief_title":"Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer","source_id_and_acronym":"NCT05861271","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HR negative • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HR negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • capecitabine • Irene (pyrotinib) • exemestane"],"overall_status":"Recruiting","enrollment":" Enrollment 1008","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 07/01/2026","primary_completion_date":" 07/01/2026","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-03-22"},{"id":"578ed237-447e-411c-ac2e-ddd1c7129e54","acronym":"OATH","url":"https://clinicaltrials.gov/study/NCT04719273","created_at":"2024-03-13T13:34:11.049Z","updated_at":"2024-07-02T16:35:14.938Z","phase":"Phase 2","brief_title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","source_id_and_acronym":"NCT04719273 - OATH","lead_sponsor":"Thomas Jefferson University","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"024bb74f-1490-40d7-83a7-0ddcbf201380","acronym":"CheckMate 7FL","url":"https://clinicaltrials.gov/study/NCT04109066","created_at":"2021-01-18T20:05:25.661Z","updated_at":"2024-07-02T16:35:15.289Z","phase":"Phase 3","brief_title":"Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer","source_id_and_acronym":"NCT04109066 - CheckMate 7FL","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • paclitaxel • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 521","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 01/16/2023","primary_completion_date":" 01/16/2023","study_txt":" Completion: 12/27/2023","study_completion_date":" 12/27/2023","last_update_posted":"2024-03-12"},{"id":"fa473daf-961e-4a3c-9a15-2a1caac72242","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905939","created_at":"2023-06-15T17:08:42.757Z","updated_at":"2024-07-02T16:35:15.833Z","phase":"","brief_title":"HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia","source_id_and_acronym":"NCT05905939","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • PGR expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PGR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 05/31/2023","start_date":" 05/31/2023","primary_txt":" Primary completion: 06/21/2024","primary_completion_date":" 06/21/2024","study_txt":" Completion: 06/21/2024","study_completion_date":" 06/21/2024","last_update_posted":"2024-03-07"},{"id":"60e95426-6d42-4d16-983e-9c8e2b245921","acronym":"BELLA","url":"https://clinicaltrials.gov/study/NCT04739670","created_at":"2021-02-05T13:56:24.494Z","updated_at":"2024-07-02T16:35:16.792Z","phase":"Phase 2","brief_title":"Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer","source_id_and_acronym":"NCT04739670 - BELLA","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" PD-L1 • ER • PGR","pipe":" | ","alterations":" PD-L1 expression • ER expression • PGR expression","tags":["PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-01"},{"id":"dd93d217-a333-439e-aa8e-029a17abbff7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06105008","created_at":"2023-10-27T17:14:07.187Z","updated_at":"2024-07-02T16:35:18.462Z","phase":"Phase 2","brief_title":"Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT06105008","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 expression • HER-2 underexpression • PGR expression","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • HER-2 underexpression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/20/2024","start_date":" 12/20/2024","primary_txt":" Primary completion: 12/20/2025","primary_completion_date":" 12/20/2025","study_txt":" Completion: 04/10/2026","study_completion_date":" 04/10/2026","last_update_posted":"2024-02-21"},{"id":"fc19fd8b-e7bb-42ac-a2ee-1c0a25c66b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT05999149","created_at":"2023-08-21T16:09:23.150Z","updated_at":"2024-07-02T16:35:18.282Z","phase":"Phase 3","brief_title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","source_id_and_acronym":"NCT05999149","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 424","initiation":"Initiation: 08/20/2023","start_date":" 08/20/2023","primary_txt":" Primary completion: 08/30/2025","primary_completion_date":" 08/30/2025","study_txt":" Completion: 08/30/2027","study_completion_date":" 08/30/2027","last_update_posted":"2024-02-21"},{"id":"ae5a0e32-c5dd-4ae6-83e1-84b2f1b61b9f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02971761","created_at":"2021-01-18T14:36:31.515Z","updated_at":"2024-07-02T16:35:18.941Z","phase":"Phase 2","brief_title":"Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT02971761","lead_sponsor":"City of Hope Medical Center","biomarkers":" HER-2 • ER • PGR • AR","pipe":" | ","alterations":" HER-2 negative • AR positive • ER expression • PGR expression","tags":["HER-2 • ER • PGR • AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • AR positive • ER expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ostarine (enobosarm)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 08/16/2022","study_completion_date":" 08/16/2022","last_update_posted":"2024-02-19"},{"id":"3ec445cf-798e-4ad2-a912-f09ad90f4afa","acronym":"KEYNOTE 721","url":"https://clinicaltrials.gov/study/NCT03310957","created_at":"2021-01-18T16:21:08.891Z","updated_at":"2024-07-02T16:35:19.546Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT03310957 - KEYNOTE 721","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" HER-2 expression • PGR expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ladiratuzumab vedotin (SGN-LIV1A)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 03/31/2024","primary_completion_date":" 03/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-13"}]